FY2026 EPS Estimates for JANX Reduced by Leerink Partnrs

Janux Therapeutics, Inc. (NASDAQ:JANX) – Analysts at Leerink Partnrs decreased their FY2026 earnings per share (EPS) estimates for Janux Therapeutics in a research report issued on Tuesday, December 3rd. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings per share of ($6.13) for the year, down from their prior estimate of ($6.12). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Janux Therapeutics’ FY2027 earnings at ($5.92) EPS and FY2028 earnings at ($4.25) EPS.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company’s revenue for the quarter was down 82.6% on a year-over-year basis.

Other research analysts have also issued research reports about the stock. HC Wainwright increased their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday. UBS Group assumed coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target on the stock. Stifel Nicolaus lifted their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday. Finally, BTIG Research raised their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $79.90.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $64.99 on Thursday. Janux Therapeutics has a 52 week low of $7.79 and a 52 week high of $71.71. The firm’s 50-day simple moving average is $50.60 and its 200 day simple moving average is $46.10. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -56.67 and a beta of 3.29.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently modified their holdings of the business. Plato Investment Management Ltd raised its position in shares of Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the last quarter. Amalgamated Bank lifted its position in shares of Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the period. Summit Securities Group LLC acquired a new position in shares of Janux Therapeutics in the 2nd quarter worth approximately $29,000. Finally, Virtu Financial LLC boosted its stake in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after purchasing an additional 2,419 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Buying and Selling at Janux Therapeutics

In other news, CEO David Alan Campbell sold 15,000 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total value of $1,005,000.00. Following the completion of the transaction, the chief executive officer now directly owns 242,054 shares in the company, valued at approximately $16,217,618. This represents a 5.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,200,000 shares of Janux Therapeutics stock in a transaction that occurred on Friday, October 18th. The shares were purchased at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the transaction, the director now directly owns 9,317,246 shares in the company, valued at $416,946,758.50. The trade was a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 352,245 shares of company stock worth $17,032,336 over the last 90 days. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.